Karen Langhauser
Developing and manufacturing cell and gene therapies consistently, efficiently and at-scale has not only slowed their market entry but also has resulted in costs that are too prohibitive for most patients — but the team …
Read moreDeveloping and manufacturing cell and gene therapies consistently, efficiently and at-scale has not only slowed their market entry but also has resulted in costs that are too prohibitive for most patients — but the team …
Read moreThe pace of development in cell and gene therapy is unprecedented in the biopharmaceutical industry. Our team of indication agnostic industry experts and cutting edge development center are uniquely equipped to help the industry advance …
Read more